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Abstract
Background: We evaluated treatment decisions and outcomes in a cohort of predominately Caucasian patients
with EGFR mutation-positive (EGFR Mut+) non-small-cell lung cancer (NSCLC).
Methods: REASON (NCT00997230) was a non-interventional study in German patients with stage IIIB/IV NSCLC.
Secondary endpoints for EGFR Mut + NSCLC included progression-free survival (PFS), overall survival (OS), adverse
event (AE) management, and pharmacoeconomic outcomes.
Results: Among 334 patients with EGFR Mut + NSCLC, tyrosine kinase inhibitors (TKIs) were the most common first-line
therapy (56.6%, 53.0% gefitinib). Among patients who received TKIs/gefitinib before first disease progression, PFS was
longer compared with those who did not receive a TKI (median 10.1/10.0 vs. 7.0 months; HR 0.67/0.69; log-rank p = 0.012/
p = 0.022). OS was longer for those patients who ever received a TKI/gefitinib during their complete therapy course
compared with those who never received a TKI (median 18.4/18.1 vs. 13.6 months; HR 0.53/0.55; p = 0.003/p = 0.005).
Total mean first-line treatment healthcare costs per person were higher for those receiving TKIs (€46,443) compared with
those who received chemotherapy (€27,182). Mean outpatient and inpatient costs were highest with chemotherapy.
Rash, diarrhea, and dry skin were the most commonly reported AEs for patients receiving gefitinib.
Conclusions: In REASON, TKI therapy was the most common first- and second-line treatment for EGFR Mut + NSCLC,
associated with increased drug costs compared with chemotherapy. Patients who received gefitinib or a TKI ever during
their complete therapy course had prolonged PFS and OS compared with patients who did not receive a TKI.
Trial registration: The trial was registered on October, 2009 with ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/
NCT00997230?term=NCT00997230&rank=1
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Background
Non-small cell lung cancer (NSCLC) accounts for 85–90%
of lung cancers [1]. Among those patients with NSCLC,
mutations in the epidermal growth factor receptor (EGFR)
are present in 30–40% of Asian patients and 10–20% of
white patients [2]. EGFR tyrosine kinase inhibitors (TKIs),
such as gefitinib have demonstrated efficacy compared with
chemotherapy in patients with locally advanced or meta-
static NSCLC with activating mutations of the TK domain
of the EGFR [3, 4]. EGFR testing is now a standard approach
in the work-up of patients with advanced NSCLC and is
recommended by the ESMO Clinical Practice European
guidelines and German lung cancer guidelines [1, 5].
The primary aim of this non-interventional study, Regis-
try for the Epidemiological and Scientific evaluation of
EGFR mutation status in patients with newly diagnosed lo-
cally advanced or metastatic NSCLC (REASON), was to
generate data on EGFR mutation status from a large cohort
of predominantly Caucasian patients and to correlate it
with clinicopathological characteristics. Detailed primary
endpoint results from REASON are reported in a separate
publication [6]. In summary, among 4200 evaluable pa-
tients, 431 (10.3%) had EGFRmutation-positive (Mut+) dis-
ease. The odds of EGFR mutation were significantly higher
(P < 0.0001) in females versus males (odds ratio 1.85; 95%
confidence interval 1.48, 2.32), never smokers versus ever
smokers (3.64; 2.91, 4.56), and adenocarcinoma versus
other histological sub-types (2.94; 2.17, 4.08).
In this paper, we report the results for the secondary
endpoints of REASON, including detailed analyses of
treatment decisions, clinical outcome, safety and toler-
ability (restricted to patients with EGFR Mut + NSCLC
who received gefitinib), and pharmacoeconomic out-
comes. We also report explorative analyses of clinical
outcomes in patients with EGFR Mut + NSCLC who re-
ceived gefitinib, which was the most commonly pre-
scribed first-line EGFR-TKI.
Methods
The study design has been reported in detail elsewhere
[6]. Briefly, this was a national, multicenter, prospective,
observational study carried out in 149 centers in
Germany in patients with newly diagnosed stage IIIB/IV
NSCLC (NCT00997230). Patients were treated and
assessed under real-life conditions and data were taken
from the electronic case report form.
Given the non-interventional design of the study, in-
tervals for follow-up were conducted according to the
routine practice of the centers. Responses were docu-
mented according to the radiologist’s report (and not ac-
cording to pre-specified criteria) and could be
radiological or clinical, as judged by the investigator.
Formal Response Evaluation Criteria In Solid Tumors
(RECIST) was not performed.
Patients were ≥18 years with histologically con-
firmed stage IIIB/IV NSCLC and suitable for first-line
treatment, but not amenable to curative surgery or
radiotherapy, and with suitable tumor tissue available
for EGFR testing [6]. Participation was until docu-
mentation of the first-line treatment decision. Patients
with EGFR Mut + NSCLC receiving first-line therapy,
and not participating in other interventional studies,
could continue until patients’ decision to withdraw,
death, or loss to follow-up.
Endpoints
The primary endpoint of the study has been re-
ported previously [6]. Secondary endpoints were an-
alyzed only for patients with EGFR Mut + disease
who were not participating in other clinical trials,
with the exception of first-line treatment decisions
and concomitant therapy, which were investigated in
all patients.
Treatment decisions were recorded for first-line and
planned second-line treatments. Multiple agents could
be recorded for treatment decisions. Amendments to
the protocol allowed for extended data capture (sub-
ject to consent of patients and data cut-off at 31 Oc-
tober 2012): documentation of actual treatments
beyond first-line, extension of follow-up until patient’s
death, and retrospective documentation of the date of
death for all patients with EGFR Mut + disease (as
assessed by Ethics Committee).
Clinical outcome records included progression-free
survival (PFS), overall survival (OS), and response rate
(RR) (complete response plus partial response). Disease
control rate was originally designated as an endpoint but
could not be determined due to the unknown duration
of stable disease resulting from the lack of a standard-
ized frequency of follow-up documentation.
Reported adverse events (AEs) for supportive treat-
ments and AE management associated with first-line
treatment in patients receiving gefitinib were re-
corded. AEs reported more than once for a patient,
and with at least one occurrence considered by the
physician to be gefitinib related, were classified as ad-
verse drug reactions (ADRs). AEs were graded ac-
cording to the National Cancer Institute Common
Terminology Criteria for Adverse Events Version 3.0.
Resource use and costs were analyzed for first-line
drug therapy (based on type and duration of therapy
and priced using the LAUER-TAXE® price list, a Ger-
man price list reflecting the official prices for pre-
scribed pharmaceuticals). Outpatient care costs were
based on the number of outpatient visits according
to the physicians’ specialty and services used, and
calculated using the Doctors’ Fee Scale within the
Statutory Health Insurance Scheme (Einheitlicher
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Bewertungsma stab). Inpatient care costs were
based on the number of inpatient stays and the
number of days in hospital associated with the event
and calculated using the national Diagnosis-Related
Groups for inpatient services. Auxiliary nursing sup-
port and incapability to work (based on changes be-
tween baseline and end of the observation period)
were also recorded; however, no costs were assigned
to these.
Statistical methods
Descriptive statistics were used with 95% confidence
limits. Binary, categorical, and ordinal parameters were
summarized by means of absolute numbers and percent-
ages (including ‘missing data’ as a valid category). Statis-
tical tests, which were performed two-sided at a 5% level
of significance, were descriptive-exploratory.
A multivariate logistic regression analysis of factors in-
fluencing first-line therapy decisions (TKI vs. no TKI) was
conducted including: mutational status known at therapy
initiation, age, gender, smoking status, tumor histology,
disease status at diagnosis, Eastern Cooperative Oncology
Group performance status, tumor stage, and tumor grade
(Grade 1 [well differentiated] to Grade X [cannot be
assessed]). For clinical outcomes, analysis was performed
by receipt of TKI/gefitinib vs. no TKI. The Kaplan-Maier-
method was used to estimate PFS and OS. Patients with-
out an event at data cut-off were censored cases.
For pharmacoeconomic analyses, descriptive statistics
for the costs were computed for continuous variables
over the observation period. Subgroup analysis was per-
formed according to therapy received (chemotherapy or
TKI) in the first-line setting, including those patients
who switched therapy.
Results
Of 4243 patients enrolled into the study, baseline docu-
mentation was available for 4200 of which 4196 fulfilled
all inclusion criteria with a total of 431 (10.3%) patients
tested positive for EGFR Mut + tumors. The disposition
of patients through the study has been previously re-
ported [6]. Documented decision of first-line treatment
was collected for 2946 patients (69%; 2481 EGFR
mutation-negative [Mut-; 58%], 131 EGFR Mut un-
known [3%], and 334 EGFR Mut + [7%]). The majority of
patients (84.9%) were treated in a hospital (81.7% and
85.2% of patients with EGFR Mut + and EGFR Mut- dis-
ease, respectively): 59.8% inpatients, 27.8% outpatients,
and 12.4% daytime care. A further 14.3% of patients
were treated by an oncologist in private practice and
0.8% of patients were treated by a pneumologist. During
this study, a greater proportion of patients with EGFR
Mut- disease were treated as inpatients (63.7%) com-
pared with patients with EGFR Mut + disease (32.6%).
The most common first-line treatments selected were
carboplatin (45.5%), cisplatin (33.9%), and pemetrexed
(28.2%) (Table 1). TKIs/gefitinib were received as first-
line therapy in 8.2%/6.2% of all patients and 56.6%/
53.0% of patients with EGFR Mut + NSCLC (n = 334).
Combination chemotherapy, generally platinum-based,
was received in 35.0% of patients with EGFR Mut + dis-
ease; 78.5% of EGFR Mut- patients received combination
chemotherapy and 12.9% received monochemotherapy.
The most commonly used agents for patients with EGFR
Mut- disease were carboplatin (48.5%), cisplatin (36.2%),
and pemetrexed (30.4%).
At follow-up, 58.8%/55.0% of 320 patients with EGFR
Mut + NSCLC had received TKI/gefitinib therapy, 21.9%
were receiving combination chemotherapy, and 10.0%/
9.4% had switched from combination chemotherapy to
TKI/gefitinib therapy. First-line therapy was continued
as maintenance in 71 (22.2%) patients with EGFR Mut +
NSCLC, mainly planned to be gefitinib (44 patients).
There was an indication that older patients were more
likely to receive TKIs than younger patients (odds ratio
1.05, 95% CI 1.01–1.09, P = 0.01). Reasons why patients
did not receive a TKI were not collected.
The most common second-line therapy choice among
122 patients with EGFR Mut + disease was TKI therapy
followed by pemetrexed and platinum agents (Fig. 1). Nine
patients received second-line treatment within a clinical
study. Among the 26 patients receiving third- and
subsequent-line treatment, pemetrexed was the most com-
monly used treatment, followed by a TKI (Fig. 1). Of the
320 EGFRMut + patients with follow-up visits, 242/213 had
documented TKI/gefitinib treatment (17 documented as
planned TKI treatment). No TKI treatment was docu-
mented for 61 patients during the REASON study.
Clinical outcomes
Of the 334 patients with EGFR Mut + disease and docu-
mented first-line treatment, 320 were assessed for clin-
ical outcome, of which 220/206 had received a TKI/
gefitinib during first-line treatment. The mean number
of documented tumor evaluations per patient was 4.9
among those receiving first-line TKIs and 4.1 among
those not receiving TKIs.
Among the 320 patients assessed for clinical outcome,
the estimated median OS and PFS was 17.2 months and
9.1 months, respectively (Table 2). Among groups of pa-
tients analyzed, OS and PFS were longer in the follow-
ing: female versus male; never smoker versus ever
smoker (Table 2). Additionally, PFS was longer in the
following: adenocarcinoma versus non-adenocarcinoma;
TKI-sensitive versus TKI-insensitive EGFR mutations.
Of those patients who received a TKI/gefitinib before
first disease progression, PFS was longer compared with
those who did not receive a TKI (Fig. 2a and b). Analysis
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of OS showed no significant difference between these
patient populations (Fig. 2c and d). However, longer OS
was reported in those patients who ever received a TKI
during their complete therapy course compared with
those who never received a TKI: median OS 18.4 vs.
13.6 months; HR 0.53; log-rank p = 0.003 (Fig. 3a). A
similar outcome was shown for those patients who ever
received gefitinib compared with those who never re-
ceived a TKI: median OS 18.1 vs. 13.6 months; HR 0.55;
log-rank p = 0.005 (Fig. 3b).
RR was 50.9% overall (Table 2) and was higher in the
following groups: female versus male; never smoker ver-
sus ever smoker; ever EGFR inhibitor versus never EGFR
inhibitor; TKI-sensitive versus TKI-insensitive EGFR
mutations.
Pharmacoeconomic endpoints
The three first-line treatment groups comprised chemo-
therapy (n = 90), TKI (n = 159), and switch to TKI (n = 31).
Total cost of treatment was highest for the TKI group
(€46,443) and lowest for the chemotherapy group
(€27,182). For all three groups, cost of drug was the main
expenditure. As a proportion of the total costs, drug costs
were higher with TKI and switch therapy (75.5% and 76.7%,
respectively) compared with chemotherapy (57.1%). In
terms of mean outpatient and inpatient costs, the chemo-
therapy group had the highest costs and the switch group
the lowest (Additional file 1: Table S1).
The number of patients with a documented nursing aux-
iliary decreased during the course of observation in the
chemotherapy group (13.7% vs. 12.7%) and increased in the
TKI and switch groups, by 5.4 percentage points (15.5% vs.
20.9%) and 16.1 percentage points (22.6% vs. 38.7%), re-
spectively. The proportion of patients without a nursing
auxiliary listed at the final visit was 62.6%, 60.8%, and 51.6%
for the TKI, chemotherapy, and switch groups, respectively.
The number of patients with an employment relation-
ship decreased throughout the observation period in all
three groups. The biggest changes were seen in the
switch group (25.8% to 3.2%), compared with the
chemotherapy (28.4% to 8.8%) and TKI (18.2% to 7.5%)
groups. However, the chemotherapy group had a higher
proportion of patients with an unknown employment re-
lationship at the end of treatment (26.5%) than the TKI
(17.1%) and switch (9.7%) groups. At the last visit, the
proportions of patients with full-time employment in the
Table 1 First-line treatment decisions
n, % EGFR Mut+
n = 334
EGFR Mut-
n = 2481
EGFR Mx
n = 131
Total
N = 2946
Agent
Carboplatin 74 (22.2) 1203 (48.5) 62 (47.3) 1339 (45.5)
Cisplatin 60 (18.0) 897 (36.2) 43 (32.8) 1000 (33.9)
Pemetrexed 39 (11.7) 754 (30.4) 38 (29.0) 831 (28.2)
Gemcitabine 37 (11.1) 603 (24.3) 36 (27.5) 676 (22.9)
Vinorelbine 43 (12.9) 586 (23.6) 41 (31.3) 670 (22.7)
Paclitaxel 21 (6.3) 284 (11.4) 8 (6.1) 313 (10.6)
Gefitinib 177 (53.0) 6 (0.2) 0 183 (6.2)
Bevacizumab 18 (5.4) 142 (5.7) 1 (0.8) 161 (5.5)
Docetaxel 3 (0.9) 97 (3.9) 1 (0.8) 101 (3.4)
Etoposide 1 (0.3) 76 (3.1) 3 (2.3) 80 (2.7)
Erlotinib 12 (3.6) 46 (1.9) 3 (2.3) 61 (2.1)
Other 0 19 (0.8) 1 (0.8) 20 (0.7)
Cetuximab 0 3 (0.1) 0 3 (0.1)
Type of treatment
Combination chemotherapy 117 (35.0) 1947 (78.5) 103 (78.6) 2167 (73.6)
Monochemotherapya 10 (3.0) 319 (12.9) 23 (17.6) 352 (11.9)
TKI 189 (56.6) 49 (2.0) 3 (2.3) 241 (8.2)
Chemotherapy + bevacizumab and/or cetuximab 18 (5.4) 141 (5.7) 1 (0.8) 160 (5.4)
Not classifiableb 0 19 (0.8) 1 (0.8) 20 (0.7)
Other 0 6 (0.2) 0 6 (0.2)
Patients with at least one specification of chemotherapy – multiple answers were permitted. Individual agents and treatment type ranked in order of decreasing
use in the total population. Mut+, mutation-positive; Mut-, mutation-negative; Mx, mutation unknown/non-evaluable; TKI, tyrosine kinase inhibitor. aCarboplatin,
cisplatin, docetaxel, etoposide, gemcitabine, paclitaxel, pemetrexed, vinorelbine. bTherapy schemes included ‘other’ substances (from free text entries)
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chemotherapy, TKI, and switch groups were 4.9%, 5.3%,
and 3.2%, respectively.
Safety
Over half of the patients receiving gefitinib reported at least
one AE (58.1%), of which rash, diarrhea, and dry skin were
the most common AEs (Table 3) and ADRs. A total of 20
grade 3–5 ADRs were reported, including two patients each
with grade 3 rash, diarrhea, and nausea and two grade 4 re-
actions (diarrhea and thrombosis/thrombus/embolism).
Serious AEs were reported for 49 patients (22.1%), the
most frequent of which were cardiac ischemia/infarction
and constitutional symptoms, other (2.3%, each), followed
by diarrhea and cystitis (1.8%, each). Eight patients (3.6%)
had AEs leading to discontinuation of treatment with gefi-
tinib, including diarrhea (n = 4) and nausea (n = 2). There
were 11 deaths, only one of which was considered to be
related to treatment with gefitinib (hemorrhage, pulmon-
ary/upper respiratory – bronchopulmonary not otherwise
specified).
Discussion
To date, the REASON study represents the largest data-
set of information on EGFR mutations in Caucasian pa-
tients with NSCLC. In the REASON study, 10.3% of
patients were tested positive for EGFR mutations, similar
to the European population (12%) in ASSESS, a large
multicentre, non-interventional diagnostic study in pa-
tients with advanced NSCLC [7].
In patients with EGFR Mut +NSCLC who received a
TKI (or gefitinib as their TKI) before first disease progres-
sion, PFS was prolonged by about three months compared
with those who did not receive a TKI. The RR was higher
in patients receiving first-line TKI than in those not re-
ceiving a TKI (53.2% vs. 45.0%). Median OS was similar
between those patients who received a TKI or gefitinib be-
fore first disease progression compared with those who
did not receive a TKI. These outcomes for PFS, OS, and
RR parallel those of clinical trials comparing TKIs with
standard doublet chemotherapy regimens [3, 4, 8].
A survival analysis of patients with EGFR Mut +NSCLC
who ever received a TKI (or gefitinib as their TKI) during
the course of their treatment revealed an increase in median
OS of approximately five months compared with those who
never received a TKI. However, when interpreting these data
it should be considered that by virtue of surviving longer,
patients may have received a greater number of treatments
(including EGFR-TKIs) compared with those patients with
poorer prognosis. This may have biased the REASON OS
analysis in favor of those patients who ever received a TKI
during their entire treatment course (n = 242) compared
with those who never received a TKI (n = 61).
Fig. 1 Second- and third-line treatment in patients with EGFR Mut + NSCLC More than one agent could be reported. *Other = experimental
(n = 4 s-line), afatinib (n = 3 s-line), experimental afatinib (n = 2 third-line), gefitinib/placebo (n = 1 s-line), trofosfamide (n = 1 s-line). †Data for
patients receiving second-line treatment are a combination of planned treatment (n = 63 patients who did not consent to collection of data for
second-line treatment) and actual treatment (n = 59 patients who consented to collection of data for second and subsequent lines of treatment).
Mut+, mutation-positive; NSCLC, non-small-cell lung cancer
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Table 2 OS, PFS, and RR in patients with EGFR Mut + NSCLC
n Overall survival Progression-free survival Response rate
Median
(months)
95% CI Median
(months)
95% CI n %
Overall 320 17.2 15.1–19.8 9.1 8.5–10.3 163 50.9
Gender
Female 200 20.4 17.2–23.8 10.3 9.4–12.6 110 55.0
Male 120 12.2 9.6–17.0 6.8 5.1–8.8 53 44.2
P < 0.001a P < 0.001a P = 0.078b
Histology
Adenocarcinoma 286 17.0 15.1–19.5 9.3 8.7–10.5 148 51.7
Non-adenocarcinoma 33 18.4 12.2–NA 6.9 5.1–21.3 15 45.5
P = 0.82a P = 0.616b
Smoking habit
Ever smoker 168 15.1 13.6–18.1 8.1 6.8–10.3 79 47.0
Never smoker 150 20.4 17.0–26.5 10.2 9.1–12.0 83 55.3
P = 0.014a P = 0.029a P = 0.172b
First-line therapy
Ever EGFR inhibitor 220 16.4 14.3–20.3 9.6 8.8–11.1 118 53.6
No EGFR inhibitor 100 18.1 15.1–23.5 8.7 6.3–11.2 45 45.0
Ever gefitinib 206 16.4 14.2–20.4 9.6 8.6–10.9 111 53.9
TKI 188 17.4 14.7–20.4 9.7 8.5–11.4 100 53.2
Gefitinib 176 17.4 14.7–20.4 9.6 8.1–11.3 94 53.4
Chemotherapy 100 18.1 15.1–23.5 8.7c 6.3–11.2 45 45.0
Chemotherapy→ TKI 32 13.9 9.1–NA 9.2 8.6–21.6 18 56.3
Chemotherapy→ gefitinib 30 10.3 8.6–21.6 13.8 8.6–NA 17 56.7
TKI maintenance planned 57 19.8 15.0–NA 10.3 8.7–16.3 38 66.7
No TKI maintenance planned 263 16.4 14.2–19.1 9.0 7.7–10.3 125 47.5
TKI from start 158 16.4 13.1–20.3 9.7 7.6–11.4
Change to TKI/planned TKI maintenance 76 17.9 14.8–NA 10.0 8.7–14.8
No TKI 86 18.0 14.2–22.5 8.1 6.1–11.2
TKI treatmentd, e
TKI from start 188 17.4 14.7–20.4 9.7 8.5–11.4
TKI switch/planned maintenance 46 17.0 10.0–NA 10.0 8.6–21.4
No TKI (first + maintenance) 86 18.0 14.2–22.5 8.1 6.1–11.2
TKI documented 229 17.9 15.0–20.5 10.1 8.9–11.7
Gefitinib documented 206 17.4 14.8–20.4 10.0 8.8–11.4
Planned TKI documented 12 NA NA 8.7 3.6–NA
No TKI documented 79 15.4 13.8–22.5 7.0 5.1–9.4
TKI treatmente, f
TKI documented 242 18.4 16.3–21.8
Gefitinib documented 213 18.1 15.5–21.4
Planned TKI documented 17 17.0 10.0–NA
No TKI documented 61 13.6 9.3–15.4
EGFR mutation
TKI-sensitive 231 18.1 15.5–20.9 10.2 9.1–11.7 132 57.1
TKI-insensitive 24 17.9 6.9–NA 5.4 4.0–9.4 8 33.3
P = 0.044b
OS, PFS, and RR by demographic and clinico-pathological characteristics, and therapy in patients with EGFR Mut + NSCLC. aLog-rank test. bChi-squared test. cIncludes
two patients in whom the therapeutic agent was changed within first-line treatment but the new agent was not documented. dTKI until first documented tumor
progression. eAnalysis not prespecified. fPatients who ever received a TKI as part of their complete therapy course
CI, confidence interval; NA, not available; NSCLC, non-small-cell lung cancer; RR, response rate; OS, overall survival; PFS, progression-free survival; TKI, tyrosine kinase inhibitor
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Fig. 2 KM estimates of PFS and OS: patients with EGFR Mut + advanced NSCLC by therapy Kaplan-Meier estimates of progression-free survival
(a and b) and overall survival (c and d), of patients with EGFR Mut + advanced NSCLC who received either a TKI (a and c) or gefitinib (b and d)
prior to first disease progression compared with those patients who did not receive a TKI prior to first disease progression. KM, Kaplan-Meier; Mut
+, mutation-positive; NSCLC, non-small-cell lung cancer; TKI, tyrosine kinase inhibitor
Fig. 3 KM estimates of OS: patients with EGFR Mut + advanced NSCLC who ever received a TKI Kaplan-Meier estimates of overall survival of
patients with EGFR Mut + advanced NSCLC who ever received either a TKI (a) or gefitinib (b) during their entire course of treatment compared
with those who did not receive a TKI. KM, Kaplan-Meier; Mut+, mutation-positive; NSCLC, non-small-cell lung cancer; TKI, tyrosine kinase inhibitor
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Previous real world studies suggested that patients
with EGFR Mut + disease who receive targeted therapy
survive longer [9, 10]. In contrast the EPICLIN-lung
study did not show any benefit, most likely because
TKIs were often used without selection for EGFR mu-
tation [11]. To date no significant differences in PFS
between gefitinib and erlotinib have been reported in
real world studies [12, 13].
In the REASON study, first-line treatments for all
patients commonly included platinum agents and
pemetrexed, similar to the findings from MUTACT (a
French observational study on the management of pa-
tients with NSCLC adenocarcinoma) [14]. Altogether,
6.2% of patients in the REASON study received gefi-
tinib as first-line treatment, fewer than reported in
the MUTACT study (23%). There were also fewer pa-
tients with EGFR Mut + NSCLC receiving a TKI first-
line in the REASON study (56.6%) compared with the
MUTACT study (76%). As previously reported, this
possibly reflects patients with acute symptoms initiat-
ing first-line chemotherapy while waiting for EGFR
mutation test results and who subsequently switch to
an EGFR-TKI once a positive mutation test was con-
firmed [6]. The proportion of patients with EGFR
Mut + NSCLC who ever received a TKI during their
entire treatment course was 80% (242/303 patients).
This is broadly in line with an Asian retrospective co-
hort study of patients with advanced NSCLC, in
which 88% of the patients with EGFR Mut + NSCLC
received a TKI at some point in their treatment (first-
, second-, or third-line) [15]. The majority of patients
in REASON with EGFR Mut + NSCLC who received
an EGFR-TKI first-line were prescribed gefitinib over
erlotinib; this could be explained by the regulatory
status of the EGFR-TKIs at the time of the REASON
study. Gefitinib was approved for use in patients with
locally advanced or metastatic NSCLC with activating
mutations of EGFR-TK in July 2009, whereas erlotinib
was approved as a first-line monotherapy in the same
group of patients in September 2011, 2 years after the
start of REASON [16, 17]. Pemetrexed was the most
commonly used second- and third-line treatment for
patients with EGFR Mut + NSCLC, followed by erloti-
nib and gefitinib.
The cost of treating patients during first-line therapy
until progression was 40% lower in the chemotherapy
group than in the TKI group. For all three groups, drug
costs were the main expense, followed by inpatient costs.
Drug costs for chemotherapy were around half com-
pared with the TKI and switch groups. However, the
highest mean outpatient and inpatient costs were docu-
mented for chemotherapy patients. It should be noted
that the AE profile of gefitinib in the REASON study
was consistent with that described in the Summary of
Product Characteristics [18]. At the end of the observa-
tion period, more patients in the TKI group did not have
a nursing auxiliary listed compared with the chemother-
apy group (62.6% vs. 51.6%). Taken together, these data
suggest EGFR-TKIs as first-line treatment in patients
with EGFR Mut + NSCLC results in fewer medical inter-
ventions than with chemotherapy. This is supported by a
study on the impact of targeted treatment on direct
medical costs of patients with advanced NSCLC, which
showed targeted agents for patients with EGFR Mut +
NSCLC lowered the mean monthly medical costs by
prolonging survival and diminishing the use of other
medical resources [19].
Table 3 AEs in patients with EGFR Mut + NSCLC treated with
gefitinib (≥ 2% of patients)
n
(N = 222)
%
All 129 58.1
Dermatology/skin
Rash: acne/acneiform 53 23.9
Dry skin 24 10.8
Nail changes 14 6.3
Pruritus/itching 14 6.3
Dermatology/skin – other 11 5.0
Hair loss/alopecia 9 4.1
Rash/desquamation 8 3.6
Gastrointestinal
Diarrhea 40 18.0
Nausea 17 7.7
Vomiting 8 3.6
Cardiac general
Cardiac ischemia/infarction 5 2.3
Constitutional symptoms
Constitutional symptoms – other 6 2.7
Fatigue (asthenia, lethargy, malaise) 5 2.3
Ocular/visual
Other 6 2.7
Hemorrhage/bleeding
Hemorrhage, pulmonary/upper respiratory – nose 5 2.3
Neurology
Neuropathy: sensory 5 2.3
Pulmonary/upper respiratory
Dyspnea (shortness of breath) 5 2.3
Renal/genitourinary
Cystitisa 4 1.8
Adverse events by CTC symptoms related to gefitinib and serious adverse
events related and not related to gefitinib. AE, adverse event; CTC, Common
Toxicity Criteria; NSCLC, non-small-cell lung cancer. aIncludes one patient in
whom cystitis was not related to gefitinib and was not serious
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The numbers of patients with employment relation-
ships at the end of the observation period were low in
all treatment groups. They were particularly low for
switch patients (3.2% vs. 8.8% for chemotherapy and
7.5% for TKI therapy). However, the larger number of
patients with an unknown employment relationship at
the end of observation in the chemotherapy group com-
pared with the other two groups challenges the inter-
pretation of these data.
Conclusions
Findings from the REASON study secondary endpoints
provide a valuable insight into current treatment pat-
terns, clinical outcomes and resource use in patients
with EGFR Mut + NSCLC in Germany. In summary, RR,
PFS and OS with first-line EGFR-TKI treatment for pa-
tients with EGFR Mut + advanced NSCLC are in line
with expectations based on previous clinical trials. OS
analysis across the entire treatment course reveals a
benefit in those patients who ever received an EGFR-
TKI vs those who did not, which is in line with other
real-world evidence [10]. The cost of first-line EGFR-
TKI treatment is more expensive than chemotherapy;
however, the highest mean outpatient and inpatient costs
were documented for chemotherapy patients, and at the
end of the observation period, more patients in the TKI
group did not have a nursing auxiliary listed compared
with the chemotherapy group.
Additional file
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